Healthcare provider profile · identity verified

Michael J. Her, M.D.

Internal Medicine · BUENA PARK, CA · NPI 1932156221

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	501	146
Amlodipine Besylate	Amlodipine Besylate	339	91
Losartan Potassium	Losartan Potassium	270	81
Metformin Hcl	Metformin Hcl	239	80
Lisinopril	Lisinopril	224	66
Gabapentin	Gabapentin	183	40
Levothyroxine Sodium	Levothyroxine Sodium	178	49
Rosuvastatin Calcium	Rosuvastatin Calcium	124	41
Alendronate Sodium	Alendronate Sodium	116	29
Ozempic	Semaglutide	115	20
Ibuprofen	Ibuprofen	105	32
Carvedilol	Carvedilol	104	31
Furosemide	Furosemide	104	29
Jardiance	Empagliflozin	98	24
Tamsulosin Hcl	Tamsulosin Hcl	97	28
Metoprolol Succinate	Metoprolol Succinate	81	22
Pravastatin Sodium	Pravastatin Sodium	80	21
Eliquis	Apixaban	79	20
Pioglitazone Hcl	Pioglitazone Hcl	78	27
Spironolactone	Spironolactone	78	26
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	70	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	69	19
Tramadol Hcl	Tramadol Hcl	69	29
Benazepril Hcl	Benazepril Hcl	68	17
Finasteride	Finasteride	67	19
Albuterol Sulfate Hfa	Albuterol Sulfate	65	25
Metoprolol Tartrate	Metoprolol Tartrate	64	20
Pantoprazole Sodium	Pantoprazole Sodium	64	28
Clonidine Hcl	Clonidine Hcl	62	18
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	61	44
Torsemide	Torsemide	61	18
Allopurinol	Allopurinol	59	15
Ezetimibe	Ezetimibe	56	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	56	18
Omeprazole	Omeprazole	56	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	55	18
Diclofenac Sodium	Diclofenac Sodium	51	21
Triamcinolone Acetonide	Triamcinolone Acetonide	48	22
Glimepiride	Glimepiride	47	18
Duloxetine Hcl	Duloxetine Hcl	46	suppressed
Clopidogrel	Clopidogrel Bisulfate	44	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	44	suppressed
Nifedipine Er	Nifedipine	43	suppressed
Prednisone	Prednisone	43	20
Hydrochlorothiazide	Hydrochlorothiazide	42	suppressed
Fluticasone Propionate	Fluticasone Propionate	41	20
Simvastatin	Simvastatin	41	12
Escitalopram Oxalate	Escitalopram Oxalate	39	13
Methocarbamol	Methocarbamol	38	suppressed
Sertraline Hcl	Sertraline Hcl	37	suppressed
Azithromycin	Azithromycin	35	22
Alprazolam	Alprazolam	34	suppressed
Hydralazine Hcl	Hydralazine Hcl	34	suppressed
Trazodone Hcl	Trazodone Hcl	34	11
Methylprednisolone	Methylprednisolone	33	23
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	33	27
Lovastatin	Lovastatin	30	suppressed
Famotidine	Famotidine	29	suppressed
Donepezil Hcl	Donepezil Hcl	28	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	28	suppressed
Solifenacin Succinate	Solifenacin Succinate	28	suppressed
Mirtazapine	Mirtazapine	27	suppressed
Valsartan	Valsartan	27	suppressed
Montelukast Sodium	Montelukast Sodium	26	suppressed
Pregabalin	Pregabalin	26	suppressed
Synthroid	Levothyroxine Sodium	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Temazepam	Temazepam	25	suppressed
Xarelto	Rivaroxaban	25	suppressed
Ketoconazole	Ketoconazole	24	12
Metformin Hcl Er	Metformin Hcl	24	11
Lorazepam	Lorazepam	23	suppressed
Rizatriptan	Rizatriptan Benzoate	23	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	13
Digoxin	Digoxin	21	suppressed
Atenolol	Atenolol	20	suppressed
Trulicity	Dulaglutide	19	suppressed
Myrbetriq	Mirabegron	18	suppressed
Naproxen	Naproxen	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Folic Acid	Folic Acid	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Bydureon Bcise	Exenatide Microspheres	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Linzess	Linaclotide	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	14	suppressed
Tresiba Flextouch U-200	Insulin Degludec	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	13	suppressed
Ramelteon	Ramelteon	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Indomethacin	Indomethacin	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Lactulose	Lactulose	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Primidone	Primidone	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Serevent Diskus	Salmeterol Xinafoate	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error